Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, Arad M.
Arow M, et al. Among authors: freimark d.
Cardiovasc Diabetol. 2020 Jan 10;19(1):7. doi: 10.1186/s12933-019-0980-4.
Cardiovasc Diabetol. 2020.
PMID: 31924211
Free PMC article.